Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort studyReport as inadecuate

Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study - Download this document for free, or read online. Document in PDF available to download.

BMC Cardiovascular Disorders

, 11:46

First Online: 26 July 2011Received: 12 January 2011Accepted: 26 July 2011


BackgroundWhile the factors for poor adherence for treatment with statins have been highlighted, the impact of their combination on adherence is not clear.

AimsTo estimate adherence for statins and whether it differs according to the number of cardiovascular risk factors.

MethodsA cohort study was conducted using data from the main French national health insurance system reimbursement database. Newly treated patients with statins between September 1 and December 31, 2004 were included. Patients were followed up 15 months. The cohort was split into three groups according to their number of additional cardiovascular risk factors that included age and gender, diabetes mellitus and cardiovascular disease using co-medications as a proxy. Adherence was assessed for each group by using four parameters: i proportion of days covered by statins, ii regularity of the treatment over time, iii persistence, and iv the refill delay.

Results16,397 newly treated patients were identified. Of these statin users, 21.7% did not have additional cardiovascular risk factors. Thirty-one percent had two cardiovascular risk factors and 47% had at least three risk factors. All the parameters showed a sub-optimal adherence whatever the group: days covered ranged from 56% to 72%, regularity ranged from 23% to 33% and persistence ranged from 44% to 59%, but adherence was better for those with a higher number of cardiovascular risk factors.

ConclusionsThe results confirm that long-term drug treatments are a difficult challenge, particularly in patients at lower risk and invite to the development of therapeutic education.

KeywordsHydroxymethylglutaryl-CoA Reductase Inhibitors Risk factors Medication adherence Databases, Factual Pharmacoepidemiology Insurance, Health, Reimbursement List of abbreviationsATCAnatomical Therapeutic Chemical

CVDCardiovascular disease

CVCardiovascular risk

CMAContinuous Multiple-interval measures of medication Availability-

CMGContinuous Multiple-interval measures of medication Gaps

CHDCoronary Heart Disease.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2261-11-46 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Philippe Latry - Mathieu Molimard - Bernard Dedieu - Thierry Couffinhal - Bernard Bégaud - Karin Martin-Latry


Related documents